Search - tctmd.com

Displaying 121 - 140 of 280

Sort: Relevancy | Date

News Industry News

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

October 14, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Industry News

Boston Scientific Announces Scheduled Presentations At TCT 2015

October 08, 2015

News Daily News

OPTIMAX: First-in-Human Results Promising for Biocompatible Cobalt-Chromium Stent

Yael L. Maxwell

September 14, 2015

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

News Conference News ESC 2015

ABSORB Trials Pit BRS Against Second-Generation DES

Caitlin E. Cox

September 02, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Daily News

COMPARE: EES Maintains Advantage Over PES at 5 Years

Salynn Boyles

July 30, 2015

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Daily News

Meta-analysis Confirms Late Safety of Second-Generation DES

L.A. McKeown

June 10, 2015

News Daily News

ISAR-DESIRE 3: Drug-Coated Balloon Shows Durable Antirestenotic Effect in DES Restenosis

L.A. McKeown

June 03, 2015

Advertisement

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

Boston Scientific Announces Scheduled Presentations At TCT 2015

OPTIMAX: First-in-Human Results Promising for Biocompatible Cobalt-Chromium Stent

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

ABSORB Trials Pit BRS Against Second-Generation DES

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

COMPARE: EES Maintains Advantage Over PES at 5 Years

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

Meta-analysis Confirms Late Safety of Second-Generation DES

ISAR-DESIRE 3: Drug-Coated Balloon Shows Durable Antirestenotic Effect in DES Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content